The basket trial Keynote-158 resulted in the approval by the FDA of pembrolizumab as a second-line treatment in cervical and endometrial cancers with PD-L1 and dMMR/MSI-H status, respectively. The gene discussed is CD274; the disease is endometrial cancer.